Novavax Inc (NVAX)

47.07
+0.94(+2.04%)
After Hours
47.00
-0.07(-0.15%)
- Real-time Data
  • Volume:
    2,684,683
  • Day's Range:
    44.84 - 47.69
  • 52 wk Range:
    41.33 - 277.80

NVAX Overview

Prev. Close
46.13
Day's Range
44.84-47.69
Revenue
1.4B
Open
45.86
52 wk Range
41.33-277.8
EPS
-17.69
Volume
2,684,683
Market Cap
3.68B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
4,596,336
P/E Ratio
-
Beta
1.57
1-Year Change
-68.81%
Shares Outstanding
78,134,595
Next Earnings Date
Aug 10, 2022
What is your sentiment on Novavax?
or
Market is currently closed. Voting is open during market hours.

Novavax Inc News

Novavax Inc Analysis

Novavax Inc Company Profile

Novavax Inc Company Profile

Employees
1541

Novavax, Inc., along with its wholly owned subsidiaries, Novavax AB and Novavax CZ, is a biotechnology company. The Company promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuySellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuyBuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyNeutralStrong SellStrong Sell
  • 80 easy
    1
    • hopefully
      0
    • when?
      0
  • More than 1000 people signed up for novavax vaccine in a small city state of sinnapore. Looking forward for fda meeting on 6/7. Will go parabolic after fda approval
    0
    • 7 of June we will know if we get approval from FDA. Dont see why they wond get it but of course you never know
      0
      • 35?
        2
        • If Novavax beats Moderna to the combine covid and flu vaccine, this will be the prefered vaccine all over the world, for now Nvax is ahead of Moderna in this deveplment. Im also happy about the Malaria vaccine they are developing, in 2019 there where 230 million that were infected.
          0
          • The European Medicines Agency (EMA) announced on Friday that it started the evaluation of the (NASDAQ:NVAX) COVID-19 vaccine for use as a booster shot in adults.The regulator greenlighted the protein- based vaccine branded as Nuvaxovid for the prevention of COVID- 19.
            0
            • Need more than booster...210k doses administered since NVAX was approved in Europe. I guess they will not even reach 1m dosis by the end of year....they will have to throw all the 13m distributed them all away - with a shelf life a 6months...I do not think Eurpoe will order anymore
              3
            • cc cc good news is that whole population needs to be vaccinated again in Q3-4
              0
          • Any boõks about trading psychology?
            0
            • the only one you have to is from George Sorros the theory of reflexivity he is the only one that made money from stocks and not from books..
              0
          • Its like when the SP500 is up, Nvax goes down south. This stock is a wierd one.
            0
            • so why is it up today when tech have really gone down
              1
              • NVAX up over $8 and over$60! Wait for the programmed trades to kick in. Short sellers have 3 days to cover or add funds to their margin accts. Next week we will see another run up!
                0